Johnson & Johnson
(XSWX:JNJ)
CHF
205.1
-3.8 (-1.82%)
Market Cap: 494.51 Bil
Enterprise Value: 521.16 Bil
PE Ratio: 29.35
PB Ratio: 7.52
GF Score: 76/100 Johnson & Johnson at Cowen Health Care Conference (Virtual) Transcript
Mar 07, 2022 / 02:10PM GMT
Joshua Thomas Jennings
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst
Good morning. I'm Josh Jennings from the Cowen medical devices research team, representing my colleagues, Brian Kennedy, Eric Anderson, [Michael Jackson] and [Ajay Suman]. We are pleased to kick off our track with Mathai Mammen, the Executive Vice President of Pharmaceuticals Research & Development of the Janssen franchise within Johnson & Johnson. Mathai, great to see you this morning. Thanks so much for participating in our conference this year.
Mathai Mammen
Johnson & Johnson - EVP of Pharmaceuticals, R&D
Wonderful to be here. And thank you, Josh.
Questions & Answers
Joshua Thomas Jennings
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst
So I know you and your team had a big event back in November, and wanted to dig a little bit deeper into the pharma R&D strategy and pipeline. And I'd like to start off with just -- and Janssen has had quite a run, a
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot